SCHEMBL753307

SCHEMBL753307

Cc1n[c]cc(Nc2cccnc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
RAD52 P43351 1/20 0.41
PIK3CA P42336 3/20 0.38
GRM5 P41594 2/20 0.38
RAB9A P51151 4/20 0.38
ADRA2A P08913 2/20 0.38
ADRA2B P18089 2/20 0.38
ADRA2C P18825 2/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
CCNK O75909 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCND3 P30281 1/20 0.38
CDK9 P50750 1/20 0.38
CDK6 Q00534 1/20 0.38
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL753154 0.82 MAPT (0.47) KMT2ARAB9AMAPTKDM4ECDK2
SCHEMBL753408 0.75 KDM4E (0.36) KMT2APIK3CARAB9AKDM4ECCNA2
SCHEMBL750723 0.75 ABCG2 (0.49) KMT2ARAB9AMAPTKDM4ECDK2
SCHEMBL753277 0.74 GOT1 (0.41) PIK3CAMTOR
SCHEMBL751535 0.73 LMNA (0.42) KMT2ARAB9AMAPTKDM4EHPGD
SCHEMBL754397 0.71 MAPT (0.53) KMT2ARAB9AMAPTKDM4ESMN1; SMN2
SCHEMBL29793056 0.70 KIF11 (0.60) KMT2ARAD52RAB9AADRA2AADRA2B
SCHEMBL1368828 0.70 KIF11 (0.60) KMT2ARAD52RAB9AADRA2AADRA2B
Ethane SCHEMBL18228141 0.68 ADRA2A (0.55) KMT2ARAD52RAB9AADRA2AADRA2B
SCHEMBL751478 0.68 MAPT (0.43) KMT2ARAB9AMAPTCDK2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD KMT2A 2120/4885RAD52 3218/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.